Repros Receives Guidance From FDA Regarding Clinical Hold Status of Proellex(R)
Posted By HSMN NewsFeed on April 30, 2010
FDA recommends modification of study design to be conducted if clinical hold is to be lifted
THE WOODLANDS, Texas–(HSMN NewsFeed)–Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced that a teleconference was held with the FDA to review the clinic… BiopharmaceuticalsRepros Therapeutics, Proellex, uterine fibroids, endometriosis (Source: HSMN NewsFeed)
Comments
Leave a Reply
Please note: Comment moderation is currently enabled so there will be a delay between when you post your comment and when it shows up. Patience is a virtue; there is no need to re-submit your comment.
You must be logged in to post a comment.